{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:49:35Z","timestamp":1753890575446,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100337"],"award-info":[{"award-number":["82100337"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20210402016GH"],"award-info":[{"award-number":["20210402016GH"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>QT interval prolongation and ventricular arrhythmias (VAs) induced by osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, are life-threatening complications. However, no consensus has been achieved regarding their management. Overdrive pacing has been shown to be effective in shortening the QT interval and terminating torsade de pointes (TdP). Here, we report a case of osimertinib-induced QT prolongation accompanied by frequent VAs and TdP. Osimertinib was immediately discontinued after it was identified as the etiology for QT prolongation and VAs. A temporary pacemaker and overdrive pacing were used after other anti-arrhythmia treatments had failed and successfully shortened the QTc interval and terminated VAs. Repeated Holter monitoring at 1 week showed no remaining VAs or TdP, and the pacemaker was removed. Routine electrocardiography (ECG) surveillance was conducted afterward, and three- and 6-month follow-ups showed good recovery and normal ECG results. Vigilance is required for rare vital arrhythmias in patients taking osimertinib, and ECG surveillance should be conducted.<\/jats:p>","DOI":"10.3389\/fcvm.2022.934214","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T08:56:35Z","timestamp":1664441795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Overdrive pacing in the acute management of osimertinib-induced ventricular arrhythmias: A case report and literature review"],"prefix":"10.3389","volume":"9","author":[{"given":"Yanyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumaraswamy","family":"Nanthakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, egfr-mutated advanced nsclc","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity","volume":"1","author":"Anand","year":"2019","journal-title":"JACC: CardioOncology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a world health organization pharmacovigilance study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/j.hrthm.2017.10.036","article-title":"2017 Aha\/Acc\/Hrs guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/annonc\/mdz415","article-title":"First-line egfr tki therapy in non-small-cell lung cancer: looking back before leaping forward","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"602762","DOI":"10.3389\/fonc.2020.602762","article-title":"Development of egfr tkis and options to manage resistance of third-generation egfr tki osimertinib: conventional ways and immune checkpoint inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"Azd9291 in egfr inhibitor\u2013resistant non\u2013small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"NEJM."},{"key":"B8","doi-asserted-by":"publisher","first-page":"viii500","DOI":"10.1093\/annonc\/mdy292.011","article-title":"Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: a combined analysis of two phase iii randomized controlled trials","volume":"29","author":"Thein","year":"2018","journal-title":"Ann Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.2017-0425","article-title":"Fda benefit-risk assessment of osimertinib for the treatment of metastatic non-small cell lung cancer harboring epidermal growth factor receptor T790m mutation","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac adverse events in egfr-mutated non-small cell lung cancer treated with osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e13939","DOI":"10.7759\/cureus.13939","article-title":"Successful management of refractory torsades de pointes due to drug-induced long qt syndrome guided by point-of-care monitoring of ionized magnesium","volume":"13","author":"Matsuura","year":"2021","journal-title":"Cureus."},{"key":"B12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s13691-020-00450-2","article-title":"Osimertinib-induced cardiac failure with qt prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma","volume":"10","author":"Ikebe","year":"2021","journal-title":"Int Cancer Confer J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12890-020-01217-4","article-title":"A case of torsades de pointes induced by the third-generation egfr-tki, osimertinib combined with moxifloxacin","volume":"20","author":"Bian","year":"2020","journal-title":"BMC Pulm Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jtho.2019.11.029","article-title":"Occurrence of ventricular fibrillation in a patient with lung cancer receiving osimertinib","volume":"15","author":"Kaira","year":"2020","journal-title":"J Thorac Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer","year":"2021","journal-title":"J Clin Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","article-title":"Prevention, diagnosis, and management of radiation-associated cardiac disease: jacc scientific expert panel","volume":"74","author":"Desai","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bcp.12726","article-title":"Pharmacological treatment of acquired qt prolongation and torsades de pointes","volume":"81","author":"Thomas","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1586\/14737140.2016.1162103","article-title":"The safety and efficacy of osimertinib for the treatment of egfr t790m mutation positive non-small-cell lung cancer","volume":"16","author":"Gao","year":"2016","journal-title":"Expert Rev Anticancer Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/cpdd.467","article-title":"Absolute bioavailability of osimertinib in healthy adults","volume":"8","author":"Vishwanathan","year":"2019","journal-title":"Clin Pharmacol Drug Development."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.934214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T08:56:39Z","timestamp":1664441799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.934214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":19,"alternative-id":["10.3389\/fcvm.2022.934214"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.934214","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"934214"}}